- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06030557
PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP) (Prep-RN)
PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure
During the initial encounter, the nurses will complete program enrollment forms (consents and disclosures as approved by IRB), medical history, and risk assessment. If needed, the RN will facilitate a 4th generation rapid HIV test or draw HIV serology. A general review of systems, focused physical exam with emphasis on sexually transmitted infections and signs of seroconversion is provided, including identifying signs of genitourinary infection.
The nurse will order labs per standing order and performs blood draw. Pre-test and Post-test counseling with HIV and STI testing is provided at this time. Upon receipt of a negative HIV rapid or serology test, PrEP-RN provides a 7-14 day supply of samples with a 30-day prescription of FTC/TDF (Truvada) or a 30-day prescription of FTC/TAF (Descovy) per standing order.
At each follow-up visit, client's self-efficacy, attitudes/beliefs about PrEP, general health indicators, and social determinants of health, such as access to transportation and housing status, are recorded. Process evaluation will be performed to determine relationships of these variables and PrEP adherence, implementation (12 months), and continuation/dissemination (year 2) phases of the study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The following study design is an alternative to the existing protocol at CAN clinics. The point of care will be RN-led, as opposed to the Provider. The Provider will still retain safety and protocol oversight, but the RN will make the clinical decisions. Findings of this study will demonstrate the relative efficacy of the nurse-led PrEP services in comparison to the traditional provider-led services.
During the initial three months of the study period, CAN will hire and train two registered nurses with licensure in the State of Florida. These nurses will work with Shannon DiPalmo, MSW, CANs Vice President for Community Engagement and other staff to identify community, faith-based organizations, and colleges who serve the priority populations. CAN will establish memoranda of agreement with these organization to allow regular visits by nurses to meet with participants in safe, private spaces where PrEP services can be provided in person or through telehealth.
When these relationships are established, the RNs will work with the partner to schedule PrEP encounters. CAN plans to enroll a minimum of 210 study participants at a minimum of six different locations.
During the initial encounter, the nurses will complete program enrollment forms (consents and disclosures as approved by IRB), medical history, and risk assessment. If needed, the RN will facilitate a 4th generation rapid HIV test or draw HIV serology. A general review of systems, focused physical exam with emphasis on sexually transmitted infections and signs of seroconversion is provided, including identifying signs of genitourinary infection (e.g., discharge, lesions, or pain), rectal infection (anal pain, tenesmus, or discharge). This exam also includes an inspection of the oral mucosa for signs of primary or secondary syphilis. The nurse will order labs per standing order and performs blood draw. Pre-test and Post-test counseling with HIV and STI testing is provided at this time. Upon receipt of a negative HIV rapid or serology test, PrEP-RN provides a 7-14 day supply of samples with a 30-day prescription of FTC/TDF (Truvada) or a 30-day prescription of FTC/TAF (Descovy) per standing order. The RN schedules a 2-week follow-up phone call with the patient and a 4-week follow-up and lab-draw visit. At the 2-week follow-up call, the RN will ensure all lab results have been reviewed with the patient and discuss PrEP tolerability and adherence. At the 4-week follow-up, the RN will repeat steps in the initial visit, facilitate renewal of the electronic medication prescription, and review medication adherence.
At each follow-up visit, client's self-efficacy, attitudes/beliefs about PrEP, general health indicators, and social determinants of health, such as access to transportation and housing status, are recorded. Process evaluation will be performed to determine relationships of these variables and PrEP adherence, implementation (12 months), and continuation/dissemination (year 2) phases of the study. Outcome evaluation will occur after start-up and will include pre and post-enrollment rates of STI, rates of unplanned pregnancy, and post enrollment HIV seroconversion. The demographics characteristics of clients enrolled in the study will be compared to CANs existing PrEP populations served in traditional clinical settings. Qualitative information on barriers to PrEP initiation, barriers to adherence, and rationale for participation interruption/termination will be obtained by the PrEP nurses during monthly check-in appointments and telephone interviews. A portion of the study nurses' FTE will be dedicated to rapid analysis and reporting. This work will be managed in-kind by the Principal Investigator, Dr. Laura Armas-Kolostroubis, MD with 5% of FTE, with co-investigators Aleida Torres, DHSc., APRN with 30% FTE and Katy Wendel R.N., BSN with 15% FTE. Additional statistical analysis will be provided by Max Wilson, Ph.D. Final study publications will be completed by a panel of CAN stakeholders, including medical and prevention subject-matter experts (SMEs) and priority population members.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33316
- Recruiting
- CAN Community Health
-
Contact:
- Gabby Brito
- Phone Number: 754-701-6920
- Email: gbrito@cancommunityhealth.org
-
Lake Worth, Florida, United States, 33460
- Recruiting
- CAN Community Health
-
Contact:
- Abra Khan
- Phone Number: 561-867-9991
- Email: Akhan@cancommunityhealth.org
-
Miami Beach, Florida, United States, 33139
- Recruiting
- CAN Community Health
-
Contact:
- Mark Kinkel
- Phone Number: 305-514-0813
- Email: Mkinkel@cancommunityhealth.org
-
Miami Gardens, Florida, United States, 33055
- Recruiting
- CAN Community Health
-
Contact:
- Abra Khan
- Phone Number: 786-800-5631
- Email: Akhan@cancommunityhealth.org
-
Plantation, Florida, United States, 33317
- Recruiting
- CAN Community Health
-
Contact:
- Gabby Brito
- Phone Number: 754-701-6911
- Email: gbrito@cancommunityhealth.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Gay and bisexual men of color, cisgender women of color, and transgender women, transgender men, heterosexual men, Caucasian cisgender men and women individuals at risk for HIV and STI's, Individuals completing nPEP services. Between the ages of 18 and 65.
Exclusion Criteria:
- Minors younger than age 18, individuals not at risk for HIV, HIV positive status, HIV seroconversion, current or historical Hepatitis B virus infection, patients who are candidates for Truvada; patient has a history of renal dysfunction or eGFR values are below 60 mL/min, patients who are candidates for Descovy; patient has advanced CKD or an eGFR less than 30 mL/min, Patient is taking contraindicated medications*, patient has a positive pregnancy test or is breastfeeding. Any other clinical or psychosocial condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Outcome 1
Time Frame: 18 months
|
Demonstrate an increase of at least 10% (n=30) of target population members enrolled in pre-exposure prophylaxis services compared to baseline (n=300)
|
18 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IN-US-412-6439
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pre-Exposure Prophylaxis (PrEP)
-
University Hospital, Clermont-FerrandCompletedPre-exposure HIV Prophylaxis (PrEP)France
-
Johns Hopkins UniversityGilead SciencesCompletedPre-Exposure Prophylaxis (PrEP)United States
-
RTI InternationalUnited States Agency for International Development (USAID); FHI 360; Wits Reproductive...CompletedRelationship Dynamics | Pre-exposure Prophylaxis (PrEP) AdherenceSouth Africa
-
Georgetown UniversityJohns Hopkins Bloomberg School of Public Health; United States Agency for International... and other collaboratorsRecruitingOral Pre-exposure Prophylaxis (PrEP) | Long-acting Injectable Cabotegravir for PrEPMalawi
-
Public Health Foundation Enterprises, Inc.San Francisco Department of Public Health; Alto PharmacyRecruitingHIV Prevention | Adherence, Medication | Risk Reduction | Pre-exposure Prophylaxis (PrEP)United States
-
San Diego State UniversityUniversity of California, San DiegoRecruitingPre-Exposure Prophylaxis (PrEP)United States
-
Beth Israel Deaconess Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingBreast Feeding | Pre-Exposure Prophylaxis (PrEP)United States, Botswana
-
Penn State UniversityRecruiting
-
Fenway Community HealthHarvard UniversityCompletedPre-Exposure ProphylaxisUnited States
-
University of North Carolina, Chapel HillGilead Sciences; Duke UniversityRecruitingPrEP | HIV Prevention | Women's Health | Prevention | Mobile Health | Pre-exposure ProphylaxisUnited States
Clinical Trials on Truvada
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingHiv | Prophylaxis | TransgenderUnited States
-
HIV Prevention Trials NetworkGilead SciencesActive, not recruitingHIV PreventionUnited States, Brazil
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute... and other collaboratorsCompletedHIV InfectionUnited States
-
FHI 360Gilead Sciences; University of North Carolina, Chapel Hill; Family Health Options... and other collaboratorsWithdrawn
-
The University of Texas Health Science Center,...Merck Sharp & Dohme LLCCompleted
-
Emory UniversityTerminated
-
University of WashingtonBill and Melinda Gates FoundationCompletedHIV Infections | HIV-1 InfectionsKenya, Uganda
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Johns Hopkins UniversityWithdrawnPregnancy | HIV-1-infection
-
Gilead SciencesCompletedChronic Hepatitis BUnited States